MX2023006368A - Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada. - Google Patents
Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada.Info
- Publication number
- MX2023006368A MX2023006368A MX2023006368A MX2023006368A MX2023006368A MX 2023006368 A MX2023006368 A MX 2023006368A MX 2023006368 A MX2023006368 A MX 2023006368A MX 2023006368 A MX2023006368 A MX 2023006368A MX 2023006368 A MX2023006368 A MX 2023006368A
- Authority
- MX
- Mexico
- Prior art keywords
- extended release
- dosing regimens
- injectable formulations
- regimens associated
- release paliperidone
- Prior art date
Links
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 title 1
- 238000013265 extended release Methods 0.000 title 1
- 239000007972 injectable composition Substances 0.000 title 1
- 229960001057 paliperidone Drugs 0.000 title 1
- VOMKSBFLAZZBOW-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-4-oxo-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-9-yl hexadecanoate Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC3=C(C)N=C4N(C3=O)CCCC4OC(=O)CCCCCCCCCCCCCCC)=NOC2=C1 VOMKSBFLAZZBOW-UHFFFAOYSA-N 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229960000635 paliperidone palmitate Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063119363P | 2020-11-30 | 2020-11-30 | |
| PCT/EP2021/062198 WO2022111860A1 (en) | 2020-11-30 | 2021-05-07 | Dosing regimens associated with extended release paliperidone injectable formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023006368A true MX2023006368A (es) | 2023-08-07 |
Family
ID=75904921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023006368A MX2023006368A (es) | 2020-11-30 | 2021-05-07 | Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada. |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11439647B2 (OSRAM) |
| EP (1) | EP4025189B1 (OSRAM) |
| JP (1) | JP2023551009A (OSRAM) |
| KR (1) | KR20230116836A (OSRAM) |
| CN (1) | CN116528836A (OSRAM) |
| AU (1) | AU2021389587A1 (OSRAM) |
| CA (1) | CA3203015A1 (OSRAM) |
| DK (1) | DK4025189T3 (OSRAM) |
| ES (1) | ES2981035T3 (OSRAM) |
| FI (1) | FI4025189T3 (OSRAM) |
| HR (1) | HRP20240800T1 (OSRAM) |
| HU (1) | HUE067072T2 (OSRAM) |
| IL (1) | IL303252A (OSRAM) |
| LT (1) | LT4025189T (OSRAM) |
| MX (1) | MX2023006368A (OSRAM) |
| PL (1) | PL4025189T3 (OSRAM) |
| RS (1) | RS65815B1 (OSRAM) |
| TW (1) | TW202222317A (OSRAM) |
| WO (1) | WO2022111860A1 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023006370A (es) | 2020-11-30 | 2023-08-07 | Janssen Pharmaceutica Nv | Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada. |
| CA3203015A1 (en) | 2020-11-30 | 2022-06-02 | Janssen Pharmaceutica Nv | Dosing regimens associated with extended release paliperidone injectable formulations |
| CN116528837B (zh) | 2020-11-30 | 2025-03-14 | 詹森药业有限公司 | 用于确保棕榈酸帕潘立酮制剂再悬浮的方法 |
| MX2024002215A (es) | 2021-08-20 | 2024-05-10 | Janssen Pharmaceutica Nv | Regímenes de dosificación asociados con formulaciones inyectables de paliperidona de liberación prolongada. |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5254556A (en) | 1988-11-07 | 1993-10-19 | Janssen Pharmaceutica N.V. | 3-piperidinyl-1,2-benzisoxazoles |
| US5158952A (en) | 1988-11-07 | 1992-10-27 | Janssen Pharmaceutica N.V. | 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use |
| TW487572B (en) | 1996-05-20 | 2002-05-21 | Janssen Pharmaceutica Nv | Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters |
| UA72189C2 (uk) | 1997-11-17 | 2005-02-15 | Янссен Фармацевтика Н.В. | Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот |
| JP5249748B2 (ja) | 2005-04-25 | 2013-07-31 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 無菌３−［２−［４−（６−フルオロ−１，２−ベンズイソオキサゾール−３−イル）−１−ピペリジニル］エチル］−６，７，８，９−テトラヒドロ−９−ヒドロキシ−２−メチル−４Ｈ−ピリド［１，２−ａ］ピリミジン−４−オンパルミチン酸エステルの製造 |
| CN101932327A (zh) | 2007-12-19 | 2010-12-29 | 詹森药业有限公司 | 与长效注射用帕潘立酮酯相关的给药方案 |
| WO2011042453A1 (en) | 2009-10-06 | 2011-04-14 | Ascendis Pharma As | Subcutaneous paliperidone composition |
| KR20120116401A (ko) | 2009-10-30 | 2012-10-22 | 얀센 파마슈티카 엔.브이. | 장기-작용성의 주사가능한 팔리페리돈 에스테르와 관련된 투약 요법 |
| EP2529757B1 (en) | 2011-05-31 | 2014-01-08 | Laboratorios Farmaceuticos Rovi, S.A. | Paliperidone implant formulation |
| WO2016157061A1 (en) | 2015-03-31 | 2016-10-06 | Wockhardt Limited | Aseptic wet milling process for paliperidone palmitate |
| FI3744326T3 (fi) | 2015-04-07 | 2024-02-02 | Janssen Pharmaceutica Nv | Annosteluohjelma pitkävaikutteisten injektoitavien paliperidoniestereiden ottamatta jääneille annoksille |
| ES3037855T3 (en) | 2017-12-14 | 2025-10-08 | SpecGx LLC | One step milling process for preparing micronized paliperidone esters |
| SMT202400077T1 (it) | 2020-11-30 | 2024-03-13 | Janssen Pharmaceutica Nv | Regimi di dosaggio associati con formulazioni iniettabili di paliperidone a rilascio prolungato |
| CA3203015A1 (en) | 2020-11-30 | 2022-06-02 | Janssen Pharmaceutica Nv | Dosing regimens associated with extended release paliperidone injectable formulations |
| CN116528837B (zh) | 2020-11-30 | 2025-03-14 | 詹森药业有限公司 | 用于确保棕榈酸帕潘立酮制剂再悬浮的方法 |
| MX2023006370A (es) | 2020-11-30 | 2023-08-07 | Janssen Pharmaceutica Nv | Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada. |
| MX2024002215A (es) | 2021-08-20 | 2024-05-10 | Janssen Pharmaceutica Nv | Regímenes de dosificación asociados con formulaciones inyectables de paliperidona de liberación prolongada. |
-
2021
- 2021-05-07 CA CA3203015A patent/CA3203015A1/en active Pending
- 2021-05-07 TW TW110116511A patent/TW202222317A/zh unknown
- 2021-05-07 EP EP21725105.7A patent/EP4025189B1/en active Active
- 2021-05-07 FI FIEP21725105.7T patent/FI4025189T3/fi active
- 2021-05-07 DK DK21725105.7T patent/DK4025189T3/da active
- 2021-05-07 JP JP2023532513A patent/JP2023551009A/ja active Pending
- 2021-05-07 MX MX2023006368A patent/MX2023006368A/es unknown
- 2021-05-07 AU AU2021389587A patent/AU2021389587A1/en not_active Abandoned
- 2021-05-07 HR HRP20240800TT patent/HRP20240800T1/hr unknown
- 2021-05-07 PL PL21725105.7T patent/PL4025189T3/pl unknown
- 2021-05-07 US US17/314,245 patent/US11439647B2/en active Active
- 2021-05-07 IL IL303252A patent/IL303252A/en unknown
- 2021-05-07 CN CN202180080431.1A patent/CN116528836A/zh active Pending
- 2021-05-07 KR KR1020237021404A patent/KR20230116836A/ko active Pending
- 2021-05-07 ES ES21725105T patent/ES2981035T3/es active Active
- 2021-05-07 RS RS20240853A patent/RS65815B1/sr unknown
- 2021-05-07 HU HUE21725105A patent/HUE067072T2/hu unknown
- 2021-05-07 WO PCT/EP2021/062198 patent/WO2022111860A1/en not_active Ceased
- 2021-05-07 LT LTEPPCT/EP2021/062198T patent/LT4025189T/lt unknown
-
2022
- 2022-09-09 US US17/941,464 patent/US12053474B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US12053474B2 (en) | 2024-08-06 |
| RS65815B1 (sr) | 2024-08-30 |
| KR20230116836A (ko) | 2023-08-04 |
| WO2022111860A1 (en) | 2022-06-02 |
| ES2981035T3 (es) | 2024-10-07 |
| IL303252A (en) | 2023-07-01 |
| CN116528836A (zh) | 2023-08-01 |
| AU2021389587A1 (en) | 2023-07-13 |
| AU2021389587A9 (en) | 2024-09-26 |
| JP2023551009A (ja) | 2023-12-06 |
| PL4025189T3 (pl) | 2024-09-23 |
| DK4025189T3 (da) | 2024-06-10 |
| EP4025189A1 (en) | 2022-07-13 |
| HRP20240800T1 (hr) | 2024-09-27 |
| TW202222317A (zh) | 2022-06-16 |
| EP4025189B1 (en) | 2024-06-05 |
| FI4025189T3 (fi) | 2024-07-02 |
| LT4025189T (lt) | 2024-07-10 |
| HUE067072T2 (hu) | 2024-09-28 |
| US20220168305A1 (en) | 2022-06-02 |
| US11439647B2 (en) | 2022-09-13 |
| US20230010558A1 (en) | 2023-01-12 |
| CA3203015A1 (en) | 2022-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202400851B (en) | Dosing regimens associated with extended release paliperidone injectable formulations | |
| MX2024009188A (es) | Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada. | |
| CL2019001292A1 (es) | Nuevos derivados de quinolina. | |
| CL2020000301A1 (es) | Nuevos derivados de quinolina. | |
| MX2020005651A (es) | Receptor de antigeno quimerico dirigido a bcma y usos del mismo. | |
| MX2019008207A (es) | Métodos para tratar el cáncer con anticuerpos anti-pd-1. | |
| CO6300949A2 (es) | Regimen de dosificacion asociado con esteres de paliperidona inyectables de accion prolongada | |
| WO2019099639A8 (en) | Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies | |
| MX2019008208A (es) | Métodos para tratar el cáncer con anticuerpos anti-tim-3. | |
| JOP20160092B1 (ar) | علاج البيتا ثلاسيميا باستخدام مصطبة لجائنية | |
| CY1116424T1 (el) | Παραγωγο αδενινης ως αναστολεας ρι3κ | |
| MX378969B (es) | Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres. | |
| BR112017000470A2 (pt) | composto, composição farmacêutica, método para modular atividade, método para tratar uma afecção | |
| MX2017014192A (es) | Composiciones y metodos de tratamiento de una enfermedad neurodegenerativa. | |
| CL2019003078A1 (es) | Nuevos derivados de pirazol bicíclicos. | |
| MX376312B (es) | Uso de antagonistas del receptor ep4 para el tratamiento de cancer de higado asociado con nash | |
| MY194576A (en) | Methods for the treatment of recurrent glioblastoma (rgbm) | |
| EA201992612A1 (ru) | Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения эндометриоза | |
| CL2021000529A1 (es) | Administración prolongada de lasmiditan por la noche para la prevención de la migraña | |
| TW201713341A (en) | Compositions and methods of treating a neurodegenerative disease | |
| EA201791227A1 (ru) | РЕЖИМ ДОЗИРОВАНИЯ АНТАГОНИСТОВ MAdCAM | |
| MX383254B (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| MA39743A (fr) | Fumarate de diméthyle et régimes de vaccination | |
| MX2019001860A (es) | Regimenes y metodos de tratamiento de la esclerosis multiple usando ofatumumab. | |
| PH12019501820A1 (en) | Pharmaceutical compositions for combination therapy |